All In Biotech

Drug Trial Radar · NCT05740215

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

A Multicenter, Open-label, Phase Ib/II Study on the Efficacy and Safety of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

158

Planned (sponsor's estimate)

Start

May 23, 2022

Primary completion

May 22, 2024

Study completion May 22, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, phase Ib/II study on the efficacy and safety of F520 combined with lenvatinib in the treatment of patients with advanced solid tumors. About 138\~158 patients with advanced solid tumors plan to be enrolled in about 30 study sites of the study. Part I: Phase Ib study evaluating the safety and tolerability of F520 combined with lenvatinib in patients with advanced solid tumors. Part II: Phase II study of F520 combined with lenvatinib in endometrial cancer and cervical cancer.

Conditions

  • Solid Tumors

Interventions

  • F520Drug

    F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)

  • LenvatinibDrug

    Lenvatinib capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serious adverse eventsTime frame: 21 days after first dose
  2. Adverse eventsTime frame: 21 days after first dose
  3. Dose-limiting toxicity (DLT)Time frame: 21 days after first dose
  4. Maximum tolerated dose (MTD)Time frame: 21 days after first dose
  5. Phase II recommended dose (RP2D).Time frame: 21 days after first dose
  6. Objective Response Rate (ORR)Time frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.